|
|
|
| Market Analysis and Countermeasures of Cervical Cancer Vaccine in China |
FENG Xue-jiao1**( ),HOU Hai-long2,YU Qiong1,WANG Jun-shu1 |
1 Institute of Science and Technology Strategy, Jiangxi Academy of Sciences, Nanchang 330096, China
2 School of Management, Nanchang University, Nanchang 330031, China |
|
|
|
Abstract As the most common gynecological malignancy, cervical cancer (human papilloma virus, HPV) is the second largest threat to women’s health. Cervical cancer vaccine is an effective way to prevent cervical cancer. Glaxosmithkline (GSK) and Merck (MSD) dominated the global market for cervical cancer vaccines until 2019. Despite the late start of cervical cancer vaccines in China, 20 vaccines have entered the clinical stage driven by domestic innovation policies. In particular, Cecolin, which is developed by INNOVAX and Xiamen University, was approved for market by National Drug Administration in April 2020. It is the first domestically developed cervical cancer vaccine in China and the third in the world. Compared with Europe and the United States and other developed countries, there is still a big gap in the promotion of cervical cancer vaccine in China, the HPV vaccine coverage rate of 9-45 years old women in China is less than 0.05%. In view of the low coverage rate of HPV vaccination, some countermeasures and suggestions were put forward, such as optimizing the review and approval process of HPV vaccine, including HPV vaccine into the national immunization program, and improving women’s understanding of HPV vaccine.
|
|
Received: 29 June 2020
Published: 11 December 2020
|
|
|
|
Corresponding Authors:
Xue-jiao FENG
E-mail: momoke914@outlook.com
|
|
|
| [1] |
冷千里. HPV疫苗在预防宫颈癌领域的专利技术综述. 科技视界, 2019,(17):208-209,158.
|
|
|
| [1] |
Leng Q L. Overview of patented technologies of HPV vaccine in the field of cervical cancer prevention. Science & Technology Vision, 2019,(17):208-209,158.
|
|
|
| [2] |
罗雅娟, 王丹丹, 杨清. HPV致女性生殖道疾病及HPV疫苗现况. 国际生殖健康/计划生育杂志, 2019,38(3):244-248.
|
|
|
| [2] |
Luo Y J, Wang D D, Yang Q. Female genital tract diseases related with HPV infection and current status of HPV vaccine. Journal of International Reproductive Health/Family Planning, 2019,38(3):244-248.
|
|
|
| [3] |
Hancock G, Hellner K, Dorrell L, et al. Therapeutic HPV vaccines. Best Practice & Research Clinical Obstetrics and Gynaecology, 2018,47:59-72.
pmid: 29108943
|
|
|
| [4] |
Pierre Van D, Chris J L M, Meijer Dorothee K, et al. A phase III clinical study to compare the immunogenicity and safety of the 9-valent and quadrivalent HPV vaccines in men. Vaccine, 2016,34:4205-4212.
doi: 10.1016/j.vaccine.2016.06.056
pmid: 27354258
|
|
|
| [5] |
缪应新, 甘洁民, 陈洁, 等. 上海地区人乳头瘤病毒基因芯片法分型检测的临床意义. 检验医学, 2015,30(6):595-598.
|
|
|
| [5] |
Miao Y X, GAN J M, Chen J, et al. Clinical significance of human papillomavirus genotyping by gene chip technology in Shanghai. Laboratory Medicine, 2015,30(6):595-598.
|
|
|
| [6] |
Eileen M B. Human papillomavirus and cervical cancer. Clinical Microbiology Reviews, 2003,16(1):1-17.
|
|
|
| [7] |
Schellenbacher C, Roden B S R, Kirnbauer R. Developments in L2-based human papillomavirus (HPV) vaccines. Virus Research, 2017,231:166-175.
doi: 10.1016/j.virusres.2016.11.020
pmid: 27889616
|
|
|
| [8] |
张师前, 王凯, 张远丽. HPV疫苗在中国的应用现状. 中国实用妇科与产科杂志, 2019,35(10):1090-1095.
|
|
|
| [8] |
Zhang S Q, Wang K, Zhang Y L. Application status of HPV vaccine in China. Chinese Journal of Practical Gynecology and Obstetrics, 2019,35(10):1090-1095.
|
|
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
